In June 2012, Semprus BioSciences Corporation was acquired by Teleflex (NYSE:TFX) . Formerly known as SteriCoat and with close ties to MIT, Semprus Bioscience Corporation is a biotechnology company developing medical devices focused to providing complication-free medical devices designed to preserve patients' long-term health and quality-of-life and to contribute to healthcare cost efficiencies by incorporating the first implantable and permanently antimicrobial surface technology - a multi-faceted approach to durable surface modifications. Current focus is to reduce thrombus accumulation and platelet adhesion on vascular access catheters with a single surface modification. Founded out of the Massachusetts Institute of Technology's Langer Lab, the company has developed the next-generation biofunctional surface platform - which is focused on achieving clinical benefits that far exceed current market offerings containing silver, heparin, and antibiotic coatings. Through covalent chemical bonding of Semprus Sustain⢠Technology, a permanent non-leaching biomaterial modification to the device surface, technology could vastly improve patient outcomes by preventing serious medical complications, such as infection, blood clots, improper healing, and cell overgrowth. The firm has worldwide licenses secured from MIT â the labs of Professors Robert Langer and Greg Stephanopoulos - and from the University of Washington, and hold numerous proprietary intellectual property filings
